Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.44 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426362 | 0.97 | PDCD1LG2 (0.45) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29531923 | 0.97 | PDCD1LG2 (0.45) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| Hydrochloric Acid SCHEMBL23404120 | 0.95 | PDCD1LG2 (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| Hydrochloric Acid SCHEMBL23404112 | 0.95 | PDCD1LG2 (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL30390006 | 0.92 | CD274 (0.52) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29697048 | 0.92 | CD274 (0.49) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL25460023 | 0.90 | ALDH1A1 (0.46) | BACE1CTSDALDH1A1 | |
| SCHEMBL31720964 | 0.90 | ENPEP (0.44) | CTSDALDH1A1 | |
| SCHEMBL30737622 | 0.89 | ECE1 (0.56) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29630774 | 0.89 | ECE1 (0.56) | BACE1CTSDPDCD1LG2CD274ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | VIROMETIX AG (CH) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | CUTA, RRP12, VAC14 | BACE1 1329/4885CTSD 2243/4885PDCD1LG2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.